Executive Summary: Cell and Gene Therapies: The Million-Dollar Claims That Are No Longer Hypothetical
LFP-09.05 — The Cost Drivers#
Kymriah costs $475,000. Yescarta costs $373,000. Breyanzi costs $410,000. Carvykti costs $465,000. Casgevy costs $2.2 million. Roctavian costs $2.9 million. These are current list prices for FDA-approved therapies with claims flowing through commercial insurance today. Medicare claims data from 2021 through 2022 documented average total costs for CAR-T therapy of approximately $499,000 per inpatient episode, including hospitalization, monitoring, and management of adverse effects. A single claim at these levels exceeds the annual claims fund for most small group level funded plans. A $2.9 million gene therapy claim in a 25-person plan is not a bad year. It is a structural event.
Six CAR-T products target hematologic malignancies. Gene therapies address sickle cell disease, severe hemophilia A, beta-thalassemia, and spinal muscular atrophy at prices exceeding $2 million per treatment. The drug price understates total episode cost. CAR-T therapy requires two to four weeks of inpatient care at a specialized cancer center. Cytokine release syndrome, occurring in a significant proportion of patients, may require ICU monitoring. Total episode cost commonly exceeds $500,000.
The stop loss mechanism functions as designed at the individual claims level: the plan’s claims fund pays the first $75,000 (the specific attachment point for a 25-person group), and the stop loss carrier pays above that threshold. The complication arrives from two directions. First, the $75,000 specific deductible, combined with routine claims for the rest of the group, can push total plan-paid claims through the aggregate corridor. Second, the stop loss carrier has just absorbed a $2.8 million claim against a premium set for a 25-person group. No small group stop loss premium anticipates a single claim of this magnitude. The carrier’s response at renewal is nonrenewal, or terms so restrictive they are functionally equivalent.
Policy limits compound the exposure. Small group stop loss policies carry aggregate limits of $1 million to $5 million per member depending on carrier and group size. A $2.9 million gene therapy claim against a $2 million per-member limit leaves $900,000 uncovered and the employer liable for the excess. Some carriers have introduced sublimits for cell and gene therapy capping coverage at $1 million or $2 million per member, others exclude specific therapies by name, and others require supplemental riders. The inconsistency across carriers including Sun Life, Voya, Symetra, and Tokio Marine HCC creates a broker placement problem: a sublimit buried in rider language may not receive scrutiny until a claim arrives.
The probability that any individual small group encounters one of these claims in a given year is low, perhaps 1 in 500 to 1 in 1,000. Applied across a TPA’s entire book over a decade of expanding indications, these claims will arrive with statistical certainty. IQVIA projects spending on next-generation biotherapeutics to reach $18 billion by 2028. Brokers reviewing stop loss policies for small group clients must examine sublimits, policy limits, and therapy-specific exclusions before placement, not after a claim demonstrates the gaps.